Eprosartan Mesylate

• CAT Number: A000911
• CAS Number: 144143-96-4
• Molecular Formula: C24H28N2O7S2
• Molecular Weight: 520.62
• Purity: ≥95%
• Synonyms: 144143-96-4; Teveten; Eprosartan methanesulfonate; Eprosartan (mesylate); Eprosartan mesilate
• Target: Angiotensin Receptor
• Solubility: >22.2mg/mL in DMSO
• Storage: Store at -20°C
• IUPAC Name: 4-[[2-butyl-5-[(E)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic acid;methanesulfonic acid
• InChI: InChI=1S/C23H24N2O4S.CH4O3S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27;1-5(2,3)4/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29);1H3,(H,2,3,4)/b18-12+
• InChIKey: DJSLTDBPKHORNY-XMMWENQYSA-N
• SMILES: CCCCC1=NC=C(N1CC2=CC=C(C=C2)C(=O)O)/C=C(\CC3=CC=CS3)/C(=O)O.CS(=O)(=O)O

Eprosartan mesylate（Cat No.:A000911）is an angiotensin II receptor antagonist used primarily for the treatment of hypertension. By selectively blocking the AT1 receptor, it inhibits the effects of angiotensin II, leading to vasodilation and reduced blood pressure. Eprosartan mesylate is effective in managing high blood pressure and may also provide renal protection in patients with diabetic nephropathy. Its pharmacokinetic profile allows for once or twice-daily dosing, enhancing patient compliance. The drug is generally well-tolerated, with side effects being mild, including dizziness and fatigue, making it a suitable option for long-term hypertension management.

Reference

1: Ahad A, Al-Saleh AA, Al-Mohizea AM, Al-Jenoobi FI, Raish M, Yassin AEB, Alam
MA. Formulation and characterization of novel soft nanovesicles for enhanced
transdermal delivery of eprosartan mesylate. Saudi Pharm J. 2017
Nov;25(7):1040-1046. doi: 10.1016/j.jsps.2017.01.006. Epub 2017 Feb 2. PubMed
PMID: 29158713; PubMed Central PMCID: PMC5681305.

2: Ahad A, Raish M, Ahmad A, Al-Jenoobi FI, Al-Mohizea AM. Eprosartan mesylate
loaded bilosomes as potential nano-carriers against diabetic nephropathy in
streptozotocin-induced diabetic rats. Eur J Pharm Sci. 2018 Jan 1;111:409-417.
doi: 10.1016/j.ejps.2017.10.012. Epub 2017 Oct 10. PubMed PMID: 29030177.

3: Ahad A, Al-Saleh AA, Al-Mohizea AM, Al-Jenoobi FI, Raish M, Yassin AEB, Alam
MA. Formulation and characterization of Phospholipon 90 G and tween 80 based
transfersomes for transdermal delivery of eprosartan mesylate. Pharm Dev Technol.
2017 May 26:1-7. doi: 10.1080/10837450.2017.1330345. [Epub ahead of print] PubMed
PMID: 28504046.

4: Ahad A, Al-Saleh AA, Al-Mohizea AM, Al-Jenoobi FI, Raish M, Yassin AEB, Alam
MA. Pharmacodynamic study of eprosartan mesylate-loaded transfersomes Carbopol(®)
gel under Dermaroller(®) on rats with methyl prednisolone acetate-induced
hypertension. Biomed Pharmacother. 2017 May;89:177-184. doi:
10.1016/j.biopha.2017.01.164. Epub 2017 Feb 24. PubMed PMID: 28237913.

5: Dangre P, Gilhotra R, Dhole S. Formulation and statistical optimization of
self-microemulsifying drug delivery system of eprosartan mesylate for improvement
of oral bioavailability. Drug Deliv Transl Res. 2016 Oct;6(5):610-21. doi:
10.1007/s13346-016-0318-7. PubMed PMID: 27465619.

6: Kalariya PD, Kumar Talluri MV, Gaitonde VD, Devrukhakar PS, Srinivas R.
Quality by design: a systematic and rapid liquid chromatography and mass
spectrometry method for eprosartan mesylate and its related impurities using a
superficially porous particle column. J Sep Sci. 2014 Aug;37(16):2160-71. doi:
10.1002/jssc.201301364. Epub 2014 Jul 10. PubMed PMID: 24913516.

7: Anandakumar K, Santhi DV, Jothieswari D, Subathrai R, Vetrichelvan T.
Development and Validation of a UV Spectrophotometric Method for the Simultaneous
Estimation of Eprosartan Mesylate and Hydrochlorothiazide in Bulk and
Formulations. Indian J Pharm Sci. 2011 Sep;73(5):569-72. doi:
10.4103/0250-474X.99017. PubMed PMID: 22923871; PubMed Central PMCID: PMC3425070.

8: Hacioğlu F, Onal A. Determination of eprosartan mesylate and
hydrochlorothiazide in tablets by derivative spectrophotometric and
high-performance liquid chromatographic methods. J Chromatogr Sci. 2012
Sep;50(8):688-93. doi: 10.1093/chromsci/bms037. Epub 2012 May 10. PubMed PMID:
22576732.

9: Qian JJ, Hu XR, Gu J, Wu SX. Eprosartan mesylate, an angiotensin II receptor
antagonist. Acta Crystallogr Sect E Struct Rep Online. 2011 Apr 1;67(Pt
4):o770-1. doi: 10.1107/S1600536811006659. Epub 2011 Mar 2. PubMed PMID:
21754064; PubMed Central PMCID: PMC3099799.

10: Teitelbaum I, Chilvers M, Reiz RJ. The angiotensin receptor blocker
eprosartan mesylate reduces pulse pressure in isolated systolic hypertension. Can
J Cardiol. 2004 Oct;20 Suppl C:11C-16C. PubMed PMID: 16807618.